Table 1.

Clinical characteristics at baseline

CharacteristicsType 2 DM (n=871)APOL1-HR (n=498)
Clinical characteristics
 Age in yr, median (IQR)60 (53–66)56 (46–66)
 Female, n (%)507 (58.2)337 (67.6)
Race
 White62 (7.1)0
 African ancestry346 (39.7)498 (100)
 Hispanic/Latino412 (47.3)0
 Other51 (5.9)0
Body Mass index in kg/m2, median (IQR)30.9 (26.6–36.1)30.5 (26.2–35.8)
Hypertension, n (%)813 (93.3)220 (44.2)
Coronary artery disease, n (%)432 (49.6)39 (7.8)
Heart failure, n (%)192 (22.0)15 (3)
Systolic BP in mm Hg, median (IQR)131.9 (123.7–143.4)129 (117–140.5)
Diastolic BP in mm Hg, median (IQR)73.4 (68.7–79.3)77 (69.5–84.5)
Follow-up time in years, median (IQR)4.5 (3.3–6.1)5.9 (3.9–7.1)
Laboratory characteristics
 Baseline eGFR in ml/min per 1.73 m2, median (IQR)68.4 (55.3–80.0)83.3 (68.9–99.4)
 Baseline UACR in mg/g, median (IQR)13.0 (4.0–66.3)11 (4.5–55)
 UACR available, n (%)486 (56%)112 (23%)
 Baseline hemoglobin A1C, median (IQR)7.0 (6.2–8.7)5.9 (5.5–6.4)
Medications
 ACE/ARB at baseline, n (%)675 (77.5)122 (24.5)
Plasma biomarker concentrations
 TNFR1, in pg/ml, median (IQR)6057.0 (4764.9–8224.4)2465 (1988–3266)
 TNFR2, in pg/ml, median (IQR)6914.2 (5332.9–9832.9)4215 (3234–5654)
 KIM-1, in pg/ml, median (IQR)323.3 (196.8–592.1)154 (96–269)
  • DM, diabetes mellitus; IQR, interquartile range; UACR, urinary albumin-creatinine ratio; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; TNFR1 and TNFR2, tumor necrosis factor receptors 1 and 2; KIM-1, kidney injury molecule-1.